AI In Drug Development: Regulatory Clarity Needed On Inspections, Human Role

Regulatory uncertainty and the biopharma industry’s longstanding aversion to risk are hindering adoption of artificial intelligence and machine learning in drug and biologic development, panelists said at a recent US FDA/CTTI workshop.